DUBLIN, Calif., April 22, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that it will release its 2013 first quarter results on Monday, April 29, 2013. James S.J. Manuso, PhD, chairman and chief executive officer, and the Astex Pharmaceuticals management team will provide details of the Company's first quarter activities.
A press release will be issued following the close of the market on April 29th. The Company will host a webcast conference call to discuss the results at 4:30 p.m. ET. A live webcast of the call will be available in the Investor Events section of the Company's website at www.astx.com. A webcast replay of the conference call will be available shortly following the event. Alternatively, you may access a replay of the conference call by dialing (855) 859-2056 (domestic) and (404) 537-3406 (international); the replay passcode number is 48856455. The webcast replay will be available for 30 days, and the telephone replay will be available for 7 days.
About Astex Pharmaceuticals
Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.
For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.
CONTACT: Timothy L. Enns Astex Pharmaceuticals, Inc. Senior Vice President Corporate Communications & Marketing Tel: +1 (925) 560-2810 E-mail: firstname.lastname@example.org Susanna Chau Astex Pharmaceuticals, Inc. Manager Investor Relations Tel: +1 (925) 560-2845 E-mail: email@example.com Alan Roemer The Trout Group Managing Director Tel: +1 (646) 378-2945 E-mail: firstname.lastname@example.org
Source:Astex Pharmaceuticals, Inc.